Etrasimod: A Next-Generation S1P Receptor Modulator for Ulcerative Colitis - Mechanistic Insights and Clinical Progress
{{output}}
Etrasimod, a next-generation oral selective sphingosine-1-phosphate (S1P) receptor modulator, has emerged as a promising treatment for immune-mediated inflammatory diseases (IMIDs), most notably moderate-to-severe ulcerative colitis (UC). Acting primarily on S... ...
